Zenlabs Ethica Ltd

Zenlabs Ethica Ltd has dispatched letters to shareholders whose email IDs are not registered, providing a weblink to access the Annual Report for the financial year 2025-26. This action complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The company also announced its 33rd Annual General Meeting (AGM) scheduled for September 29, 2026. The Annual Report and AGM notice are being sent electronically to registered email holders, while others receive the weblink via letter. Shareholders can access the report on the company's website and are encouraged to update their email addresses.

Zenlabs Ethica Ltd has filed its Annual Report for the financial year 2025-26, along with the Notice of the 33rd Annual General Meeting (AGM). The report details the company's operations, including its WHO-GMP certified pharmaceutical business, trading and distribution activities across domestic and international markets, and its position within the Preet Remedies Group. The AGM is scheduled for September 29, 2026, to adopt the audited financial statements for FY26. The company emphasizes its focus on expanding product reach, strengthening market presence through strategic alliances, and maintaining quality compliance.

Zenlabs Ethica Ltd has announced that its 33rd Annual General Meeting (AGM) for the financial year 2025-26 will be held on Tuesday, September 29, 2026, at 12:00 PM IST. The meeting will take place at the company's registered office in Chandigarh. Key agenda items include the adoption of audited financial statements for the year ended March 31, 2026, the re-appointment of Mr. Sanjay Dhir as a Director, and the re-appointment of M/s. N. Kumar Chhabra & Co. as statutory auditors for a term of five years. The notice also details the cut-off date for e-voting as September 22, 2026, and the remote e-voting period from September 26 to September 28, 2026. Additionally, the company plans to amend its Memorandum of Association.

Zenlabs Ethica Ltd announced that its Board of Directors has approved the re-appointment of M/s N Kumar Chabbra & Co., Chartered Accountants, as the statutory auditor for a term of five years. This reappointment is subject to shareholder approval at the upcoming 33rd Annual General Meeting (AGM) scheduled for September 29, 2026. The firm, with registration number 000873N, has extensive experience in audit, assurance, taxation, and accounting services. The Board also approved the convening of the AGM, the Board's Report for FY26, and the provision for e-voting for shareholders. Amendments to the Memorandum of Association were also approved, pending shareholder consent.

Zenlabs Ethica Ltd announced the reappointment of M/s N Kumar Chabbra & Co. as its statutory auditor for a term of five years, subject to shareholder approval at the upcoming 33rd Annual General Meeting (AGM). The Board of Directors, in their meeting held on September 02, 2026, also approved the convening of the AGM on September 29, 2026, and the provision for remote e-voting for shareholders. The company will submit the AGM notice and annual report for the financial year 2025-26 shortly. Additionally, the Board approved the Board's Report for the fiscal year ended March 31, 2026, and an amendment to the object clause of the Memorandum of Association, also pending shareholder consent.

Zenlabs Ethica Ltd announced the outcome of its board meeting held on September 02, 2026. The board approved the convening of the 33rd Annual General Meeting (AGM) on September 29, 2026, and the approval of the Board's Report for the financial year ended March 31, 2026. Shareholders will have the facility for remote e-voting from September 26 to September 28, 2026. Additionally, the board recommended the re-appointment of N Kumar Chabbra & Co. as statutory auditors for a term of 5 years, subject to shareholder approval. Amendments to the object clause of the Memorandum of Association were also approved, pending shareholder consent at the AGM.

Zenlabs Ethica Limited announced that its Board of Directors has approved the unaudited financial results for the quarter ended June 30, 2026. The results were reviewed by the Audit Committee and approved by the Board on August 12, 2026. The company's statutory auditors have issued an unmodified opinion on these financial results. The financial statements are prepared in accordance with Indian Accounting Standards (Ind AS) and comply with the Companies Act, 2013, and SEBI regulations. Zenlabs Ethica operates as a single-segment company focused on trading pharmaceutical formulations.

Zenlabs Ethica Ltd announced the outcome of its board meeting held on August 12, 2026. The board approved the unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The company also disseminated the Limited Review Report for the same period on its website. The financial results are prepared in accordance with Indian Accounting Standards (Ind AS) and SEBI guidelines.

Zenlabs Ethica Ltd has entered into a business agreement with V Nexxtra Lifesciences Private Limited, appointing them as the sole and exclusive distributor for its entire product portfolio across India. This domestic distribution agreement mandates V Nexxtra Lifesciences to handle marketing, promotion, sales, and distribution. The agreement includes specific terms for sales turnover targets and a commission structure, starting at 5% of Net Sales Value, with a potential increase to 5.5% for FY27-28 onwards if targets are met. V Nexxtra Lifesciences will bear all sales team expenses and ensure compliance with relevant laws.

Zenlabs Ethica Ltd has announced that its Board of Directors will convene on August 12, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The meeting will take place at the company's registered office in Chandigarh. Additionally, the company confirmed that the trading window for its securities will remain closed for insiders from July 1, 2026, until 48 hours after the declaration of the financial results.